.jpg?sfvrsn=205a5de0_2)
Precision Radiation: New Hope for Prostate Cancer Patients
A groundbreaking treatment, 225Ac-PSMA-Trillium, is demonstrating remarkable success in targeting advanced prostate cancer. Early trial results reveal the ‘search and destroy’ therapy shrank tumors or halted their growth in 83 per cent of patients, offering a potential lifeline for those with limited options.
How Does 225Ac-PSMA-Trillium Work?
This innovative approach utilizes a “homing device” to locate cancer cells throughout the body. It detects prostate-specific membrane antigen (PSMA), a protein found in elevated levels on the surface of prostate cancer cells. Once attached, the treatment delivers a potent radioactive payload designed to kill cancer cells while minimizing damage to surrounding healthy tissue. The treatment employs an alpha-emitter, releasing energy over a very short distance.
PanTHa Trial Results: A Significant Step Forward
The results, presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, come from the global PanTHa trial, led by Professor Johann de Bono at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust, and sponsored by Bayer. The trial involved 50 participants with PSMA-positive advanced prostate cancer who had previously undergone multiple treatments, including hormone therapy.
Of the 24 patients whose cancer could be measured, almost half (46 per cent) experienced tumor shrinkage, and 83 per cent achieved disease stabilization. 83 per cent of patients saw their prostate-specific antigen (PSA) levels halved, with 58 per cent experiencing a 90 per cent reduction.
Minimizing Side Effects
The most commonly reported side effect was dry mouth, which was generally mild. These promising results pave the way for larger clinical trials to further evaluate the treatment’s efficacy and safety.
A ‘Guided Missile’ for Cancer Treatment
Professor Johann de Bono described the treatment as a “guided missile,” delivering radiation directly to cancer cells. He emphasized the urgent need for more effective treatments for patients whose prostate cancer no longer responds to hormone therapies. If confirmed in larger trials, 225Ac-PSMA-Trillium could offer renewed hope.
The Future of Targeted Alpha Therapy
This treatment represents a “smarter, more targeted approach” to cancer therapy, according to Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London. By delivering radiation with precision, it has the potential to improve survival rates while reducing side effects. Research into radioisotopes for both imaging and treatment is ongoing at the ICR and The Royal Marsden.
Real-Life Impact: Jim Hilson’s Story
Jim Hilson, 79, from Leicestershire, was diagnosed with advanced prostate cancer in 2015. After exhausting standard treatment options, he joined the PanTHa trial in 2024. “Since being diagnosed with prostate cancer I’ve had chemotherapy, radiotherapy and hormone treatment, but when the treatment stopped working there were no other standard treatments available,” he said. “I joined the trial and the results have been remarkable. Across three consecutive scans, the cancer has remained stable and the treatment has successfully targeted the cancer in my vertebrae and other bones.” He continues to live a full life, running his businesses and enjoying travel.
Beyond PSMA: Expanding the Reach of Alpha Therapy
Research is expanding beyond PSMA-targeting therapies. Other molecules, such as [225Ac]Ac-macropa-pelgifatamab and [225Ac]Ac-PSMA-62, are being investigated for their potential in delivering targeted alpha therapy to various cancers. This suggests a broader future for this approach in oncology.
Frequently Asked Questions
- What is PSMA? Prostate-specific membrane antigen is a protein found in higher levels on prostate cancer cells, making it a useful target for treatment.
- What are alpha-emitters? Alpha-emitters are radioactive substances that release large amounts of energy over short distances, effectively killing cancer cells with minimal damage to surrounding tissue.
- What were the main side effects observed in the trial? The most common side effect was dry mouth, which was generally mild.
- Is this treatment widely available? 225Ac-PSMA-Trillium is currently in clinical trials and is not yet widely available.
Pro Tip: Early detection is crucial for successful prostate cancer treatment. Talk to your doctor about regular screenings and be aware of any potential symptoms.
Stay informed about the latest advancements in cancer treatment. Visit the National Cancer Institute website for more information and resources.
